Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.30 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30556676 | 1.00 | NR3C1 (0.33) | NR3C1NR3C2PLA2G1BATG4B | |
| SCHEMBL26116725 | 0.75 | — | — | |
| SCHEMBL30556591 | 0.75 | — | — | |
| SCHEMBL23115903 | 0.75 | ACSS2 (0.40) | — | |
| SCHEMBL29765901 | 0.75 | ACSS2 (0.40) | — | |
| SCHEMBL25364430 | 0.74 | RAB9A (0.34) | — | |
| SCHEMBL29447613 | 0.74 | CYP11B1 (0.35) | NR3C1 | |
| SCHEMBL26118351 | 0.74 | PKM (0.32) | — | |
| SCHEMBL25366403 | 0.70 | MAPT (0.36) | PLA2G1BATG4B | |
| SCHEMBL21996476 | 0.70 | ALDH1A1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197406-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME | 1ST Biotherapeutics, Inc. (KR) | 2025-06-19 | — | — | US | disclosed |
| EP-4499643-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME | 1st Biotherapeutics, Inc. (KR) | 2025-02-05 | — | — | EP | disclosed |
| CN-119212997-A | Indazoles as inhibitors of hematopoietic progenitor kinase 1 (HPK 1) and methods of use thereof | 第一生物治疗股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| WO-2023180976-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME | 1ST Biotherapeutics, Inc. (KR) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197406-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME | IP6K1, HIPK1, IP6K3 | NR3C1 1507/4885NR3C2 3241/4885PLA2G1B 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.